-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-512113-41-00
5
2024-11-20
Severe Asthma
-
2024-511313-38-00
4
2024-11-17
Soft Tissue Sarcoma
-
2024-513098-31-00
4
2024-11-14
Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma
-
2024-518813-24-00
1
2024-11-12
Patients with Relapsed/Refractory Acute Myeloid Leukemia or High/Very-
-
2023-508704-37-00
5
2024-11-08
Stroke
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2024-514886-21-00
6
2024-11-06
Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus
(P
-
2023-504620-26-00
4
2024-11-04
Triple negative breast cancer
-
2024-514240-93-00
10
2024-10-31
Idiopathic nephrotic syndrome (INS)
-
2023-510395-31-00
5
2024-10-30
Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Compensat
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-514606-31-00
4
2024-10-29
Patients with Biopsy-proven or radiologically-suggested BCLC A HCC eli
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2024-514241-10-00
4
2024-10-22
Kaposi's sarcoma
-
2023-504755-26-00
4
2024-10-21
Bronchiectasis
-
2024-515300-39-00
4
2024-10-18
METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA OF G
-
2023-509334-19-00
5
2024-10-17
gastro-enteropancreatic neuroendocrine tumors (GEP-NETs)
-
2023-508614-41-00
4
2024-10-15
The study will be proposed to all adult patients receiving an allogene
-
2023-508539-30-00
4
2024-10-10
Refractory Focal Onset Epilepsy
-
2023-507994-16-00
5
2024-10-07
Choroideremia (CHM)
X-Linked Retinitis Pigmentosa (XLRP)
-
2024-514610-13-00
5
2024-10-04
patients suffering from acute myocarditis confirmed on Cardiac magneti
-
2023-504986-22-00
5
2024-09-30
surgical antibiotic prophylaxis
-
2024-512921-10-00
1
2024-09-27
Advanced and/or Metastatic Solid Tumors